Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Oliver Lomas, MD DPhil, MRCP, Sarah Gooding, MD PhD, Karthik Ramasamy, MD PhD, Angela Hamblin, MD PhD, Maite Cabes, PhD, Helene Marie-Pierre Dreau, PhD, Edward Wilson, FRCPath, MRCP

Blood (2019) 134 (Supplement_1): 3062.

https://doi.org/10.1182/blood-2019-125145

Published: 2019

Journal Articles

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, B.Sc., PhD, Sally Moore, Jaimal Kothari, Andy Peniket, MD, Karthik Ramasamy, MD PhD

Blood (2019) 134 (Supplement_1): 4768.

https://doi.org/10.1182/blood-2019-128139

Published: 2019

Journal Articles

Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity

Jonathan Gibbins, BSc, PhD, Rekha Rana, Dalia Khan, Susie Shapiro, MD, Henri Grech, Karthik Ramasamy, MD PhD

Blood (2018) 132 (Supplement 1): 3300.

https://doi.org/10.1182/blood-2018-99-116006

Published: 2018

Journal Articles

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Karthik Ramasamy, MD PhD, Spyros Kolovos, PhD, Guido Nador, MD, Rosemarie Finley, Matthew Streetly, MD, Bhuvan Kishore, Neil K Rabin, MD, Andrew D Chantry, PhD MD, Kwee Yong, MD PhD, John Ashcroft, Stella Bowcock, MD BA, FRCP, FRCPath, MA, Mark T Drayson, Daniel Prieto-Alhambra, PhD MD, Cyrus Cooper, OBE, DL, FMedSci, Muhammad Kassim Javaid, MD PhD, Rafael Pinedo-Villanueva, PhD

Blood (2018) 132 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2018-99-114736

Published: 2018

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Nicola Maciocia, MBChB, BSc, MRCP, Andrew Melville, MBBS, MA (Cantab), MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Simon Cheesman, BPharm, Faye Sharpley, MBBChir, MA, MRCP, MSc, Karthik Ramasamy, MD PhD, Matthew Streetly, BMBS, MRCP, MRCPath, Matthew W Jenner, MD, Reuben Benjamin, MB, BS, FRCPath, Stephen A Schey, MD, Rakesh Popat, Shirley D'Sa, Ali Rismani, MBBS, Kwee L Yong, Neil Rabin

Blood (2016) 128 (22): 3312.

https://doi.org/10.1182/blood.V128.22.3312.3312

Published: 2016

NARROW

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Email alerts

ASH Publications

American Society of Hematology

Clinical-Grade Whole Genome Sequencing Reproduces FISH Cytogenetics and Provides Actionable Data in Newly Diagnosed Myeloma - a Pilot Study from the UK 100,000 Genomes Project

Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care

Multiple Myeloma Treatment Is Associated with Enhanced Platelet Reactivity

Elective Vs Non-Elective Hospital Admissions By Patients with Multiple Myeloma in England 2014 - 2018

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only